Literature DB >> 24852934

Pneumococcal vaccine and patients with pulmonary diseases.

Mehdi Mirsaeidi1, Golnaz Ebrahimi2, Mary Beth Allen3, Stefano Aliberti4.   

Abstract

Chronic pulmonary diseases are chronic diseases that affect the airways and lung parenchyma. Examples of common chronic pulmonary diseases include asthma, bronchiectasis, chronic obstructive lung disease, lung fibrosis, sarcoidosis, pulmonary hypertension, and cor pulmonale. Pulmonary infection is considered a significant cause of mortality in patients with chronic pulmonary diseases. Streptococcus pneumoniae is the leading isolated bacteria from adult patients with community-acquired pneumonia, the most common pulmonary infection. Vaccination against S. pneumoniae can reduce the risk of mortality, especially from more serious infections in both immunocompetent and immunocompromised patients. Patients with chronic pulmonary diseases who take steroids or immunomodulating therapy (eg, methotrexate, anti-tumor necrosis factor inhibitors), or who have concurrent sickle cell disease or other hemoglobinopathies, primary immunodeficiency disorders, human immunodeficiency virus infection/acquired immunodeficiency syndrome, nephrotic syndrome, and hematologic or solid malignancies should be vaccinated with both 13-valent pneumococcal conjugate vaccine and the pneumococcal polysaccharide vaccine 23-valent.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Invasive pneumococcal disease; Pneumococcal; Pneumonia; Pulmonary; Streptococcus pneumoniae; Vaccination

Mesh:

Substances:

Year:  2014        PMID: 24852934      PMCID: PMC4161643          DOI: 10.1016/j.amjmed.2014.05.010

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  77 in total

Review 1.  Pulmonary complications of hemoglobinopathies.

Authors:  Rekha Vij; Roberto F Machado
Journal:  Chest       Date:  2010-10       Impact factor: 9.410

2.  Heptavalent pneumococcal conjugate vaccine elicits similar antibody response as standard 23-valent polysaccharide vaccine in adult patients with RA treated with immunomodulating drugs.

Authors:  Meliha Crnkic Kapetanovic; Carmen Roseman; Göran Jönsson; Lennart Truedsson
Journal:  Clin Rheumatol       Date:  2011-09-29       Impact factor: 2.980

3.  A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years.

Authors:  T F Schwarz; J Flamaing; H C Rümke; J Penzes; C Juergens; A Wenz; D Jayawardene; P Giardina; E A Emini; W C Gruber; B Schmoele-Thoma
Journal:  Vaccine       Date:  2011-05-25       Impact factor: 3.641

Review 4.  Pneumococcal vaccination: work to date and future prospects.

Authors:  D M Musher; D A Watson; E A Dominguez
Journal:  Am J Med Sci       Date:  1990-07       Impact factor: 2.378

5.  A 5-year longitudinal follow-up study of serological responses to 23-valent pneumococcal polysaccharide vaccination among patients with HIV infection who received highly active antiretroviral therapy.

Authors:  C-C Hung; S-Y Chang; C-T Su; Y-Y Chen; S-F Chang; C-Y Yang; W-C Liu; C-H Wu; S-C Chang
Journal:  HIV Med       Date:  2009-07-29       Impact factor: 3.180

Review 6.  How effective is vaccination in preventing pneumococcal disease?

Authors:  Daniel M Musher
Journal:  Infect Dis Clin North Am       Date:  2013-03       Impact factor: 5.982

7.  Clinical and economic burden of community-acquired pneumonia in the Medicare fee-for-service population.

Authors:  Holly Yu; Jaime Rubin; Stephan Dunning; Suying Li; Reiko Sato
Journal:  J Am Geriatr Soc       Date:  2012-10-30       Impact factor: 5.562

Review 8.  Pulmonary complications of primary immunodeficiencies.

Authors:  Rebecca H Buckley
Journal:  Paediatr Respir Rev       Date:  2004       Impact factor: 2.726

9.  Randomized, single blind, controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in renal transplant recipients.

Authors:  Selma Tobudic; Veronika Plunger; Gere Sunder-Plassmann; Markus Riegersperger; Heinz Burgmann
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

10.  Effectiveness of influenza vaccination in patients with end-stage renal disease receiving hemodialysis: a population-based study.

Authors:  I-Kuan Wang; Cheng-Li Lin; Po-Chang Lin; Chih-Chia Liang; Yao-Lung Liu; Chiz-Tzung Chang; Tzung-Hai Yen; Donald E Morisky; Chiu-Ching Huang; Fung-Chang Sung
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

View more
  11 in total

Review 1.  Use and clinical interpretation of pneumococcal antibody measurements in the evaluation of humoral immune function.

Authors:  Thomas M Daly; Harry R Hill
Journal:  Clin Vaccine Immunol       Date:  2014-12-17

2.  Pneumococcal Vaccination Among Adults With Work-related Asthma.

Authors:  Katelynn E Dodd; Jacek M Mazurek
Journal:  Am J Prev Med       Date:  2017-09-27       Impact factor: 5.043

3.  Improving Influenza and Pneumococcal Vaccination Rates in Ambulatory Specialty Practices.

Authors:  Keyana N Pennant; John J Costa; Anne L Fuhlbrigge; Paul E Sax; Lara E Szent-Gyorgyi; Jonathan Coblyn; Sonali P Desai
Journal:  Open Forum Infect Dis       Date:  2015-10-01       Impact factor: 3.835

4.  Colonisation of Irish patients with chronic obstructive pulmonary disease by Streptococcus pneumoniae and analysis of the pneumococcal vaccine coverage: a non-interventional, observational, prospective cohort study.

Authors:  Hannah McCarthy; Mandy Jackson; Mary Corcoran; Martha McElligott; Elaine MacHale; Imran Sulaiman; Breda Cushen; Richard W Costello; Hilary Humpreys
Journal:  BMJ Open       Date:  2017-07-09       Impact factor: 2.692

5.  Prescribing Immunoglobulin Replacement Therapy for Patients with Non-classical and Secondary Antibody Deficiency: an Analysis of the Practice of Clinical Immunologists in the UK and Republic of Ireland.

Authors:  John David M Edgar; Alex G Richter; Aarnoud P Huissoon; Dinakantha S Kumararatne; Helen E Baxendale; Claire A Bethune; Tomaz Garcez; Siraj A Misbah; Ricardo U Sorensen
Journal:  J Clin Immunol       Date:  2018-02-08       Impact factor: 8.317

Review 6.  Treatment of Sarcoidosis: A Multidisciplinary Approach.

Authors:  Alicia K Gerke
Journal:  Front Immunol       Date:  2020-11-19       Impact factor: 7.561

7.  Factors associated with hospitalization in bronchiectasis exacerbations: a one-year follow-up study.

Authors:  Rosario Menéndez; Raúl Méndez; Eva Polverino; Edmundo Rosales-Mayor; Isabel Amara-Elori; Soledad Reyes; Tomás Posadas; Laia Fernández-Barat; Antoni Torres
Journal:  Respir Res       Date:  2017-09-30

8.  Vaccination coverage and associated factors for receipt of the 23-valent pneumococcal polysaccharide vaccine in Taiwan: A nation-wide community-based study.

Authors:  Chang-Hua Chen; Ming-Shiang Wu; I-Chien Wu
Journal:  Medicine (Baltimore)       Date:  2018-02       Impact factor: 1.889

9.  Role of Streptococcus pneumoniae infection in chronic obstructive pulmonary disease patients in Italy.

Authors:  Marco Mantero; Stefano Aliberti; Chiara Azzari; Maria Moriondo; Francesco Nieddu; Francesco Blasi; Marta Di Pasquale
Journal:  Ther Adv Respir Dis       Date:  2017-08-31       Impact factor: 4.031

Review 10.  Role of Inflammatory Risk Factors in the Pathogenesis of Streptococcus pneumoniae.

Authors:  Ifrah Sohail; Sumit Ghosh; Santhosh Mukundan; Susan Zelewski; M Nadeem Khan
Journal:  Front Immunol       Date:  2018-10-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.